Lebrikizumab (Ebglyss) for Atopic Dermatitis
Lebrikizumab (Ebglyss) for Atopic Dermatitis
November 11, 2024 (Issue: 1715)
The FDA has approved lebrikizumab-lbkz (Ebglyss –
Lilly), a subcutaneously injected interleukin (IL)-13
antagonist, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated with topical therapy in...more
- Three drugs for atopic dermatitis (Adbry, Cibinqo, and Rinvoq). Med Lett Drugs Ther 2023; 65:51.
- Dupilumab (Dupixent) for moderate to severe atopic dermatitis. Med Lett Drugs Ther 2017; 59:64.
- Drugs for atopic dermatitis. Med Lett Drugs Ther 2020; 62:89.
- DMR Davis et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024; 90:e43. doi:10.1016/j.jaad.2023.08.102
- Dupilumab (Dupixent) for asthma. Med Lett Drugs Ther 2019; 61:6.
- EL Simpson et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183:242. doi:10.1111/bjd.18898
- T Bieber et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol 2022; 187:338. doi:10.1111/bjd.21630
- AJ Okragly et al. Binding, neutralization, and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther (Heidelb) 2023; 13:1535. doi:10.1007/s13555-023-00947-7
- JI Silverberg et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388:1080. doi:10.1056/nejmoa2206714
- EL Simpson et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol 2023; 159:182. doi:10.1001/jamadermatol.2022.5534
- AA Hebert et al. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. J Dermatolog Treat 2024; 35:2324833. doi:10.1080/09546634.2024.2324833
- A Blauvelt et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023; 188:740. doi:10.1093/bjd/ljad022
- NA Hanania et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4:781. doi:10.1016/s2213-2600(16)30265-x
- J Corren et al. Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population. J Allergy Clin Immunol Pract 2024; 12:1215. doi:10.1016/j.jaip.2024.02.007
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Lebrikizumab. [Updated 2024 October 15]. Available at: https://bit.ly/4hj3720. Accessed October 24, 2024.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Lebrikizumab (Ebglyss) for Atopic Dermatitis
Article code: 1715b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
